LYEL
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Lyell provided a safety update on LYL273 and expanded its trial to Phase 1/2Jun 8, 2026
- Lyell Immunopharma initiated patient dosing in a first-of-its-kind Phase 3 head-to-head CAR-T trial for aggressive large B-cell lymphomaFeb 12, 2026
- Lyell Immunopharma acquires exclusive global rights to next-generation CAR T-cell product candidate in clinical development for metastatic colorectal cancerNov 10, 2025
- Lyell Immunopharma announces initiation of Phase 3 head-to-head CAR T-cell therapy clinical trial in aggressive large B-cell lymphoma and formation of expert steering committeeSep 3, 2025
- Lyell Immunopharma reports high rates of durable complete responses in Phase 1/2 trial of LYL314 for aggressive large B-cell lymphomaJun 17, 2025